Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden

Benzer Materyaller

• The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34(+) progenitor cells
  Yazar:: Mohr, Brigitte, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring
  Yazar:: Oelschlaegel, Uta, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
  Yazar:: Sockel, Katja, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
  Yazar:: Schönefeldt, C, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse
  Yazar:: Sockel, Katja, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)